U.a Matulonis
AuthID: R-00K-26Q
1
TITLE: Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer Full Text
AUTHORS: U.A Matulonis; B.J Monk; A.A Secord; M.A Geller; David Scott Miller ; N.G Cloven; G.F Fleming; A.E Wahner Hendrickson; Azodi, M; P.A DiSilvestro; A.M Oza; Cristea, M; J.S Berek; J.K Chan; Li, Y; Luptakova, K; S.J Hazard; K.N Moore;
PUBLISHED: 2019, SOURCE: Gynecologic Oncology, VOLUME: 154
AUTHORS: U.A Matulonis; B.J Monk; A.A Secord; M.A Geller; David Scott Miller ; N.G Cloven; G.F Fleming; A.E Wahner Hendrickson; Azodi, M; P.A DiSilvestro; A.M Oza; Cristea, M; J.S Berek; J.K Chan; Li, Y; Luptakova, K; S.J Hazard; K.N Moore;
PUBLISHED: 2019, SOURCE: Gynecologic Oncology, VOLUME: 154
